<DOC>
	<DOCNO>NCT00394186</DOCNO>
	<brief_summary>This study test hypothesis GW427353 , beta-3 adrenergic agonist , relieve IBS pain discomfort associate symptom IBS patient .</brief_summary>
	<brief_title>A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome ( IBS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Solabegron</mesh_term>
	<mesh_term>Adrenergic Agonists</mesh_term>
	<criteria>Diagnosis IBS meet Rome II criterion , screen pain score &gt; 1.5 ( 0= pain , 4 = severe pain ) Subjects meet Rome II criterion diagnosis IBS Subjects stool 7 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>GW427353</keyword>
	<keyword>b3-Adrenergic Receptor Agonist</keyword>
	<keyword>Irritable Bowel Syndrome ( IBS )</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>